Liminal BioSciences Inc. PFSCF

The Ryplazim market is much larger than first advertised

[Biofinder]

Fred’s email was encouraging. We were originally told the size of the Ryplazim (plasminogen) market was $8 Billion USD. The Thrombosis and Stroke markets alone are $47+ Billion USD and it appears now that Ryplazim will get a nice slice of that $47+ Billion USD market. 

*** Plasminogen is essential for all healing in the human body, no healing happens without plasminogen in nature, and Prometic will own the entire medical-grade plasminogen market come H1 2019 with FDA approval.

 

Per Fred: 

Ryplazim Pipeline 

§  “The TMP trial in Sweden is progressing and 5 patients have been dosed to date – the purpose of this trial is to confirm the dosing regime and formulation for external wound-healing indications including DFU. DFU remains a large and potentially very valuable longer-term opportunity – however, we have dug deeper into the wide of acute indications for Ryplazim and are prioritizing the clinical development of those such as deep vein thrombosis, complications with central venous catheters and stroke which we are now confident can be most quickly become commercial opportunities following the full licensure of Ryplazim for congenital deficiency and the appropriate regulatory approvals for these other acute indications.“

(some of the “low hanging fruit” they were speaking of)

Sent from my iPad